What an Alexander Disease Approval Means for RNA Developers

On September 3, 2026, the FDA approved zilganersen for the treatment of Alexander disease in pediatric and adult patients, marking the first disease-modifying therapy for a condition that has historically been managed through symptom control alone.¹ The approval applies to an RNA-targeted therapy administered quarterly via intrathecal injection, and it arrived alongside a Rare Pediatric Disease Priority Review Voucher granted by the agency.

How Do Diagnosis and Genetic Variability Shape Treatment Development?

Alexander disease presents across four recognized age-based forms (neonatal, infantile, juvenile, and adult), each with distinct clinical trajectories.² The neonatal form typically causes death within two years, while adult-onset cases can progress slowly over decades, sometimes with a relapsing-remitting course that mimics multiple sclerosis. This heterogeneity complicates diagnosis: confirmation requires both suggestive brain MRI findings, including a characteristic periventricular rim and basal ganglia involvement, and molecular genetic testing identifying a heterozygous pathogenic variant in the gene encoding the disease-causing protein. Sequence analysis detects a pathogenic variant in roughly 98% of cases.

Most cases arise from de novo, rather than inherited, mutations, though the disease follows an autosomal dominant pattern when passed from an affected parent, giving each child a 50% inheritance risk.² Population-based prevalence is estimated at approximately 1 in 2.7 million.

What Do the Clinical Data Show?

Approval for zilganersen was supported by a global, multicenter, randomized, double-blind, controlled study that enrolled 54 participants across 13 sites in eight countries, mostly children.¹ Participants received either the 50 mg dose, a lower 25 mg dose, or a control regimen dosed every 12 weeks over a 60-week double-blind period. In patients aged 5 and older, the therapy met its primary endpoint, showing statistically significant stabilization of gait speed as measured by the 10-Meter Walk Test compared with control. In children aged two to four, the therapy showed improvement in gross motor function as measured by a separate, well-established motor scale. Secondary and exploratory outcomes based on patient, caregiver, and clinician assessments were also generally favorable. Reported adverse events were mostly mild to moderate, and serious treatment-related events occurred less frequently in the treatment group than in the control group.

Why Does the Approval Matter for Drug Development?

For an ultra-rare disease population, running a controlled trial large enough to generate statistically meaningful results is inherently difficult.¹ In a PharmTech interview, published in April of 2025, on the challenges in developing treatments for ultra-rare diseases, Joe Katakowski, director of Research, RTW Foundation said, “[Ultra rare disease] is the most difficult space in which I've worked in preclinical drug development ever. [R]are disease foundations have challenges [to] getting access to the same resources and expertise that drug development companies would have; that's mainly due [to] their small patient population sizes.”

The program for zilganersen demonstrates a regulatory and clinical trial design pathway that other rare neurological disease developers may look to as a reference point.¹ The approval also reinforces continued FDA support for RNA-targeted modalities in central nervous system disease, an area where manufacturing and quality considerations, including intrathecal delivery, cold-chain handling, and small-batch production for ultra-rare indications, differ meaningfully from more conventional biologics. The priority review voucher awarded alongside this approval is itself a manufacturing and regulatory strategy consideration, since such vouchers can be applied to accelerate review of a future application or sold to another company, adding a financial and pipeline-planning dimension to rare disease drug development decisions.

"For decades, care for people living with Alexander disease has focused primarily on managing symptoms, without an option to modify the underlying cause of disease. The approval of ZANVASTRO for the treatment of Alexander disease represents a significant advancement in care and opens new possibilities for patients and their families." said Amy Waldman, MD, MSCE, pediatric neurologist and lead investigator for the study, Children's Hospital of Philadelphia, in a press release.¹

The therapy is expected to become available in the US in the coming weeks.¹ Regulatory submissions in Europe and Japan are anticipated in 2027 through a separate licensing partner.¹

References

1. Ionis Pharmaceuticals, Inc. ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients [press release]. Carlsbad, CA: Ionis Pharmaceuticals, Inc.; Press Release. September 3, 2026. https://ir.ionis.com/news-releases/news-release-details/zanvastrotm-zilganersen-approved-fda-first-and-only-disease
2. Johnson AB, Li R, Messing A, Brenner M. Alexander disease. In: Adam MP, Mirzaa GM, Pagon RA, et al, eds. GeneReviews®. University of Washington, Seattle; 1993-2025. https://www.ncbi.nlm.nih.gov/books/NBK1172/